Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab in non-cystic fibrosis bronchiectasis
2023-508663-70-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis comparing Itepekimab with Matched placebo (2 arms). Primary endpoint: Annualized rate of moderate or severe pulmonary exacerbations over the treatment period. Started Jun 2024; status: completed.
02
Drugs
itepekimab
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2023-508663-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508663-70-00.